Welcome to our newsroom. Here you will find all the latest news about Brystol Myers Squibb in the Netherlands. As a journalist, you will also find all press releases, contact details and visual material here.
Bristol Myers Squibb today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease.
"World Cancer Day has long taken place on February 4. Personally, I think it is important to reflect on this: recognition of a global disease that claims more and more victims every year. Cancer occurs in all stages of life: awareness can contribute to early recognition and the removal of a taboo."
The construction of the CAR T cell therapy production centre of Bristol Myers Squibb in the Leiden Bio Science Park (LBSP) is going fast. Today the highest point was reached which traditionally means a topping-off ceremony.
For all media inquiries
Senior Manager Corporate Affairs
Phone number: +31 30 300 22 22
If you are not a member of the press and have a non-media related question then find the right contact information here. This will enable us to help you faster!
Learn more about the mission, vision and values of Bristol Myers Squibb the Netherlands
More information about the medicines distributed by Bristol Myers Squibb in The Netherlands
Get an overview of our research for innovative medicines